PILA PHARMA

We're very honoured to share that the @AmDiabetesAssn (ADA), @ADA_DiabetesPro is featuring PILA PHARMA AB in the "Thought Leadership Film Series", a part of ADA’s 81st Scientific Sessions program in June 2021, starting today. #Diabetes #research #T2D youtu.be/zJc3ZUAeK0A

Stock Analysis: aktieinfo.net/filer/pilaphar…

Event: aktieinfo.net/tilmelding/

💰 Come join us for an #investment night and introduction to @PILAPHARMA and our innovate pill solution for #obesity and #diabetes! 💊 Tomorrow our CEO Gustav H. Gram will be with #AktieInfo / John Stihøj at their event in #Århus, Denmark 🇩🇰

Please find the report here: pilapharma.com/financial-repo…

(...) We will evaluate the safety following higher doses and longer treatment in a few people with obesity. Given acceptable safety, the plan will be to enroll more to be able to identify effects on weight, and prepare other activities to build on the data package for XEN-D0501"

PILA PHARMA PUBLISHES ITS ANNUAL REPORT FOR 2025 📖 CEO Gustav H. Gram comments: "2025 was a year of much activity and positive developments for @PILAPHARMA.  (...) Please find the report (in Swedish) in link in comments 📚

Link to press release: pilapharma.com/pila-pharma-up…

#PRESS: UPDATE TO PRECLINICAL RAT #OBESITY STUDIES - LOW EXPOSURE OF XEN-D0501 COULD EXPLAIN LACK OF EFFECT ON BODYWEIGHT @PILAPHARMA yesterday announced that drug exposure in the obese rat studies was very low and plausibly explains the absence of an effect on body weight.

on the conference, the partnering, the market's appetite for new mechanisms of action outside the GLP-1 sphere and the next milestones for @PILAPHARMA! 🎯 Find the interview here 🤠 biostock.se/en/2026/03/pil…

🎤🌟 "The interest is definitely still there for drugs that target other pathways than #GLP1, to achieve healthy weightloss and tolerable safety profiles" On the last day of #BIOEuropeSpring, @BioStock_SWE reached out to get our take (1/2)

🌟 All in all, it was a fruitful week and we keep focus on progressing the operations and to deepen dialogues! 🌟 #PILA / @EBDgroup / @InformaConnect (4/4)

👩🏻‍⚕️ Understand interest in applications beyond pain, such as #dermal diseases where #inflammation is a key component. 💰 Understand the M&A direction - 2025 saw a net decline in progressed assets. With looming #patentcliffs for many, the activity could increase. (3/4)

Olá & obrigado Lisboa! 🇵🇹🫱🏻‍🫲🏼 This week @PILAPHARMA CEO had the pleasure of attending #BIOEuropeSpring in sunny Lisbon! ☀️ 🫱🏻‍🫲🏼 This remains one of our favourite annual recurring events to meet with partners, discuss partnerships and kickstart new dialogues! 🧏🏻‍♂️ Key takeaways (1/4)

More infomartion about the conference and @PILA_PHARMA's participation here: informaconnect.com/bioeurope-spri… Extra info: The word "PILA" in Portuguese is mild slang for 'male genitalia'... 🤔 That should open for some interesting networking discussion 😄 @InformaConnect / @EBDgroup

🇵🇹🌟 @PILAPHARMA to participate in #BIOEuropeSpring, 23–25 march. Let's propel the new wave of biotech innovation together! CEO Gustav H. Gram will discuss our proprietary oral small molecule #TRPV1 inhibitor for #obesity, as well as the rare disease #erythromelalgia! 💊

CEO Gustav H. Gram personally exercised a total of 33,817 warrants for a total of 67,634 new shares Founder Dr. Dorte X. Gram, exercised a total of 167,102 warrants for a total of 334,204 new shares Full press release: pilapharma.com/pila-pharma-to…

#PRESS: TO2 WARRANTS CONVERTED, SHARES ARE NOW TRADABLE – CEO & FOUNDER’S PARTICIPATION DISCLOSED Full press release: pilapharma.com/pila-pharma-to…